FDA Approved: DANYELZA — Original Application (Y-mAbs Therapeutics, Inc.)

View source ↗

Summary

FDA approved DANYELZA (naxitamab) from Y-mAbs Therapeutics for pediatric patients with relapsed or refractory high-risk neuroblastoma confined to bone or bone m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• DANYELZA (NAXITAMAB)

Snippet

ORIG AP for DANYELZA (NAXITAMAB)